AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06564727 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uniportal VATS approach
Description: Uniportal VATS resection for simple pulmonary aspergilloma
Study NCT06564727 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS approach
Description: VATS resection for complex pulmonary aspergilloma
Study NCT03491306 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breflex
Description: In the recent time thermoplastic materials become quite popular in clinical practice such as nylon and acetal resins. since the 1950, poly-amide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus(3).~The major disadvantage of a nylon removable denture is the inability for a reline procedure and the lack of occlusal rests as well as rigid frameworks, that could lead to occlusal instability and sinking, especially in Kennedy class I and II cases. On the other hand, acetal resins present adequate mechanical strength to form a frame-work more rigid than nylon with retentive clasps, connectors, and supportive elements; however, the acetal resin material lacks natural translucency and vitality.
Study NCT04396665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Precam
Description: 6 months Web-App intervention related with: diet, physical activity, self-care and breast cacner risk prevention
Study NCT00691067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone
Description: 200 mg po per day x 6 weeks
Study NCT00691067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo
Study NCT02099539 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
Study NCT02297243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sinopsys Lacrimal Stent
Description: The Sinopsys Lacrimal Stent is indicated for use to create a transcaruncular ethmoid sinus access.
Study NCT03668769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet Mobile Technology
Description: Use Quitting Schedule mobile smartphone app
Study NCT03668769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies
Study NCT02911571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MMprofiler SKY92 gene signature
Description: MMprofiler is a gene expression assay system for detection of the presence (or absence) of the SKY92 high-risk gene signature to aid in the determination of the Multiple Myeloma patient's prognosis
Study NCT02749331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AdVince
Description: Virus solution for infusion in intrahepatic artery
Study NCT02669225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [18F]florbetaben
Description: PET radiotracer to image Amyloid beta (AB) load in human brain.
Study NCT03668769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03668769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Participate in individual smoking cessation program
Study NCT03707054 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Study Arm
Description: Measurements of optic nerve diameter, serum and urine osmolarity, serum vasopressin
Study NCT04865640 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Noninterventional and noninvasive
Description: The ADI At-Home CPM (Cardiopulmonary Management) System is intended for adults undergoing monitoring for cardiopulmonary conditions under the direction of a licensed medical professional to measure, record, and periodically transmit physiological data.
Study NCT00722553 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pralatrexate Injection
Description: Intravenous (IV) push administration over 3-5 minutes via a peripheral IV line containing normal saline (0.9% sodium chloride).~Initial dose: 190 mg/m2~Dose reductions per protocol: 150 mg/m2, 120 mg/m2 and 100 mg/m2 will be allowed for defined toxicity.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met.
Study NCT03712631 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tunneling technique bone augmentation
Description: horizontal ridge augmentation using mixture of xenograft,autogenous bone
Study NCT00722553 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin B12
Description: 1 mg intramuscular injection~Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate.
Study NCT03712631 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tunneling technique bone augmentation
Description: horizontal ridge augmentation using mixture of xenograft,autogenous bone
Study NCT02155569 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extraperitoneal Cesarean
Description: Pfannenstiel incision, paravesical approach to lower uterine segment extraperitoneally and Kerr incision for uterine entry
Study NCT02155569 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transperitoneal Cesarean
Description: Pfannenstiel-Kerr technique for laparatomy and uterine entry
Study NCT01243671 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Study NCT01225887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Given PO
Study NCT02869438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)
Study NCT02869438 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)
Study NCT05154201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIN1001
Description: Dose escalation of ORIN1001 as a single agent or in combination with standard of care. Dose expansion of ORIN1001 as a single agent or in combination with standard of care.
Study NCT01840618 — intervention group
Intervention type: DEVICE
Intervention: Nasal Continuous positive airway pressure (CPAP)
Description: We will initiate treatment of OSA with CPAP for 3 months in PCOS adolescents with moderate to severe OSA. Compliance will be defined as the average number of hours for which CPAP was used per night over the 12-wk treatment period. Adherence with CPAP will be defined as CPAP use ≥4 hours daily. The primary outcome variable will be insulin sensitivity measured as change in GIR. Changes in cardio metabolic variables after CPAP treatment will be expressed as a percentage of the corresponding baseline values.
Study NCT00903318 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire about family's characteristics taking about 30-35 minutes to complete.
Study NCT00890266 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collagen cross-linking with hypotonic riboflavin
Description: Topical anaesthesia, corneal epithelial debridement, application of hypotonic riboflavin 0.1% solution (20 minutes), application of UV light (30 minutes).
Study NCT02977130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Map group
Description: diabetes shared care plus conversation map intervention
Study NCT02977130 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: diabetes shared care
Study NCT03711201 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group IORE
Description: This group will undergo the IORE procedure before surgery (operation). On the day of surgery, the patient will be brought to the operating room by the anesthesiologist. Hemodynamic data (blood pressure, pulse rate, respiratory rate, SpO2) will be measured at the service, preop unit and operating room. The anxiety level in the operating room will be measured by the ST-STAI scale.
Study NCT00749515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine
Description: After a 3-day washout period from all chelation, all patients have a 12 hour infusion of 50mg/kg of deferoxamine with urine collection and pre and post blood sampling to assess iron and Total Iron Binding Capacity (TIBC) by atomic absorption.
Study NCT00749515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: After a 3-day washout period from all chelation, patients had a desferal challenge which was followed by a single dose of deferasirox, 35mg/kg orally with blood sampling taken pre-deferasirox and at intervals for 24 hours after the dose.
Study NCT00749515 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HIDA
Description: All patients had a HIDA scan to assess physiologic liver clearance capacity.
Study NCT04058418 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Completion of a short survey.
Study NCT02080858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor + Apixaban + ASA
Study NCT02080858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor + Apixaban
Study NCT03642665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natural cycle
Description: no medication
Study NCT03642665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Valerate
Description: Oestradiol valerate (Progynova, Bayer, Germany) 6mg daily will be given from day 2 of the cycle. The dose of Progynova is increased to 8mg daily if the endometrial thickness is less than 7mm after 7-10 days of Progynova use. Progynova will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Progynova will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.
Study NCT03642665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micronized progesterone
Description: Micronized progesterone (Utrogestan, Besins, Belgium) 200 mg vaginally three times daily is started as soon as the endometrial thickness is 7 mm. Utrogestan will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Utrogestan will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.
Study NCT01284582 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATH03
Description: 4 vaccinations
Study NCT03829488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasma-Lyte 148 (approx. pH 7.4) IV Infusion
Description: Plasma-Lyte 148 (approx. pH 7.4) IV Infusion is a sterile, clear, non-pyrogenic isotonic solution and when administered intravenously is a source of water, electrolytes and calories. Plasma-Lyte 148 intravenous infusion is indicated as a source of water \& electrolytes or as an alkalinising agent.
Study NCT03829488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% SODIUM CHLORIDE 9g/L injection BP
Description: Sodium chloride (0.9% saline) infusion is a sterile, non-pyrogenic solution of sodium chloride in Water for Injections. The concentration of sodium chloride is 154mmol/L. Sodium chloride (0.9%) intravenous infusion is indicated for extra-cellular fluid replacement and in the management of metabolic alkalosis in the presence of fluid loss, and for restoring or maintaining the concentration of sodium and chloride ions.
Study NCT00722553 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Folic Acid
Description: 1-1.25 mg orally~Administered daily for at least 7 days prior to enrollment, throughout the study and for at least 30 days after last dose of pralatrexate.
Study NCT03816982 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-injection bupivacaine HCl plus liposomal bupivacaine
Description: Patients in the liposomal bupivacaine with added bupivacaine HCl ISB group will be given a single injection LB ISB in the preoperative area only by faculty who are part of the regional anesthesia division. The injectate will include liposomal bupivacaine 10ml (133mg) mixed with bupivacaine HCl 0.5% 10 ml.
Study NCT03816982 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-injection bupivacaine HCl plus a subsequent bupivacaine CISB
Description: Patients in the bupivacaine CISB group will undergo catheter placement with ultrasound guidance only by faculty who are part of the regional anesthesia division. A 20 mL single bolus ISB with 0.25% bupivacaine will be administered followed by catheter infusion of 0.125% bupivacaine at a rate of 5mL/hour postoperatively by the ON-Q pump
Study NCT01606644 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: Inhalation of 100% oxygen for 90 minutes
Study NCT03148418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).
Study NCT03148418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered as directed per the parent study.
Study NCT03148418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab will be administered as directed per the parent study.
Study NCT02188225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: 12 sessions acupuncture during 12 weeks (3 sessions weekly), each session lasting 20 minutes
Study NCT02188225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoxetine
Description: 10 mg/ daily
Study NCT00591344 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive resistance training
Description: Exercise twice a week for 2 years doing either progressive resistance training. The The PRE program consisted of 11 strengthening exercises: chest press, latissimus pull downs, reverse flys, double leg press, hip extension, shoulder press, biceps curl, rotary calf (ankle plantar flexion), triceps extension, seated quadriceps extension and back extension.
Study NCT00591344 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Modified Fitness Counts
Description: The modified Fitness Counts program was taken from Chapters 2 and 3 of the Parkinson's disease: Fitness Counts booklet and focused on non-progressive stretching, strengthening and balance exercises.
Study NCT01480765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: 150mg (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to 75mg twice daily for 2 days and finally to 50 mg twice daily for 2 days
Study NCT00694707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied in capsules.
Study NCT00694707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine was supplied in capsules
Study NCT01480765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine infusion
Description: 0.1mg/kg/hr for 48 hours post operatively
Study NCT01480765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Single capsule (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to single capsule twice daily for 2 days and finally to single capsule twice daily for 2 days
Study NCT01480765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion
Description: Normal saline placebo intravenous infusion for 48 hours
Study NCT01480765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo infusion
Description: Normal saline placebo intravenous infusion for 48 hours
Study NCT04668599 — intervention group
Intervention type: OTHER
Intervention: Cardiopulmonary rehabilitation
Description: Patients will undergo standardized cardio-pulmonary rehabilitation program.
Study NCT04456673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Study NCT04438603 — intervention group
Intervention type: DRUG
Intervention: Intervention for incipient patients at low risk of disease progression
Description: Conservative treatment, if necessary use ACEI/ARB and titrated to the maximum tolerated dose, with a BP-lowering goal of \< 130/80 mm Hg
Study NCT00694707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Risperidone was supplied in capsules
Study NCT02640716 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: multi-domain internet-based adaptive training program
Description: The cognitive training will be a multi-domain adaptive training program, including processing speed, attention, long-term memory, working memory, flexibility, calculation, and problem solving. Specific training paradigms include a time perception task, visual search task, attention blink, delayed mapping task, attention span task, Go-No go task, Stroop task, task switching, and name-face match task, among others. To maintain task difficulty, the tasks will be grouped based on the task difficulty in each domain. Furthermore, each task will have various difficulty levels.
Study NCT04456673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Corticosteroid
Description: Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation
Study NCT04456673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Corticosteroid
Description: Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation
Study NCT04456673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Long-Acting Beta Agonist
Description: Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation
Study NCT04456673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Long-Acting Beta Agonist
Description: Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation
Study NCT04456673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Long-Acting Muscarinic Antagonist
Description: Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation
Study NCT04456673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Long-Acting Muscarinic Antagonist
Description: Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation
Study NCT04456673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Study NCT02797548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin only
Description: Aspirin only during surgery
Study NCT02797548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No antiplatelet therapy
Description: No antiplatelet therapy will be during surgery
Study NCT02933151 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Nutritional Supplement
Description: Selection of which supplement to give to the patients will be left to the dialysis unit's governing body as this study is not interested in a specific supplement's effect on nutrient restoration and subsequent outcomes but rather on oral replacement of amino acids regardless of the agent used.
Study NCT01257243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syrup of oxomemazine, guaifenesin and potassium iodate
Description: 5ml each 4 hours
Study NCT02640716 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo program
Description: For the control group, tasks for processing speed and attention are included. Importantly, a fixed, primary difficulty level for all participants in the control group is set.
Study NCT01682668 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral subthalamic stimulation
Study NCT03590834 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Intervention
Description: 1. Monthly interactive poster education sessions led by parent peer educators during child pick-up time. Held at Head Start Center. These sessions include family health challenges and take-home activities.~2. Three Home Visits delivered by Head Start staff. Obesity prevention goal-setting integrated into existing Head Start home visits~3. 16 semi-monthly, Family Newsletters with stories, tips, and strategies to promote healthy habits for preschool children~4. Incorporating activities related to PA, nutrition and sleep into existing Head Start Center Summer Calendars
Study NCT03590834 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Children will receive Head-Start-approved health education program for children: I Am Moving, I Am Learning. In addition, the investigators will deliver an early childhood literacy program to all active control children to increase buy-in and retention.
Study NCT05135247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 3 different types of training or control